Navigation Links
SmartGene, Inc. Enters Collaboration with Virco Lab, Inc. to Enhance HIV Genotyping and Resistance Interpretation Services in US
Date:4/20/2009

RALEIGH, N.C., April 20 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and analysis of genetic data, today announced a marketing and distribution collaboration with Virco Lab, Inc., to help US laboratories manage, analyze, and derive maximum benefit from their HIV sequences. Virco will market SmartGene, Inc.'s secure, Web-based service module, SmartGene(R) HIV, which is a unique, integrated, data management solution encompassing various interpretation algorithms, multiple genetic targets and cumulative resistance reporting.

The SmartGene HIV platform will allow laboratories using both SmartGene, Inc. and Virco services to send an order for interpretation of sequence data by Virco directly out of the SmartGene HIV module and then store the resulting virco(R)TYPE HIV-1 resistance reports within their SmartGene database.

"HIV clinicians and laboratorians understand the importance of longitudinal data to resistance assessment; they value the insight gained from reinterpreting sequences with updated algorithms and comparing results derived from different algorithms; they are interested in analyzing new genetic targets, such as Integrase and Envelope. SmartGene HIV exquisitely meets these needs," said David Ellis, President of SmartGene, Inc. "We have made excellent progress introducing our modules supporting bacterial and fungal identification by sequence analysis. As we expand the deployment of our services for virology in the US, we are delighted to enter this collaboration with Virco, a long-standing market leader for resistance testing and interpretation in the HIV field."

About SmartGene, Inc.

SmartGene, Inc. is the North American subsidiary of SmartGene GmbH, a privately-held company based in Zug, Switzerland, which provides its services worldwide. SmartGene provides web-based suites of functionality to facilitate sequence-based analysis for a variety of clinical, medical research, and veterinary applications. Constant updates to reference data and interpretive algorithms keep SmartGene's customers in step with evolving science and improve the accuracy of sequence interpretation. SmartGene's integrated services increase the speed to result for sequence-based diagnostics and improve workflow in the laboratory. Current modules from SmartGene include Bacteria, Fungi, HIV, HCV, MLST, Influenza, and HLA typing. Future applications will address human genetics as well as food and environmental pathogens. Discover more at www.smartgene.com.


'/>"/>
SOURCE SmartGene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... Inc., will hold an open house for regional manufacturers at its Maple Grove, ... from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... Winnipeg, Manitoba (PRWEB) , ... April 27, 2016 ... ... commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance ... for better understanding disease and testing novel treatments in small animal subjects. Simultaneous ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman ... as an associate in the firm’s Intellectual Property practice group. , Clients turn ... patent applications. He has an electrical engineering and computer engineering background, and experience ...
Breaking Biology Technology:
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
(Date:3/15/2016)... , March 15, 2016 Yissum ... , the technology-transfer company of the Hebrew University, announced ... of remote sensing technology of various human biological indicators. ... raising $2.0 million from private investors. ... based on the detection of electromagnetic emissions from sweat ...
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
Breaking Biology News(10 mins):